Neurolief develops proprietary digital therapeutics neuromodulation technology to treat neurological and neuropsychiatric disorders such as migraine and depression. The company’s devices either complement or provide an alternative to pharmaceutical therapies, which are often ineffective and are associated with potential short- and long-term adverse effects. Neurolief’s products are groundbreaking electronic head mounted devices designed to concurrently target major neural pathways in the head and thereby affect brain regions that are involved in control and modulation of pain and mood. These devices are intended to provide a highly effective, side-effects free treatment for the hundreds of millions of patients worldwide. Neurolief is led by a seasoned team with extensive experience and successful track record developing multiple neuromodulation devices for patients with central nervous system deficiencies.
